Alamar Biosciences Inc. announced Friday that it received FDAmarketing approval for its gram-positive bacterial test kits forin vitro diagnosis.

The test kit will determine, for up to 16 different antibiotics,which medication and what dosage will be effective in treatinga gram-positve bacterial infection.

According to Kenneth D. Miller, Alamar's chief executive, thetest kit will complement the company's previously approvedtest kit for gram-negative bacterial infections.

The Sacramento, Calif., company develops, manufactures andmarkets in vitro disposable tests for bacterial identification andantibiotic dosage effectiveness.

Alamar filed with the Securities and Exchange Commission inJune for an initial public offering of 850,000 units, eachconsisting of one share of common stock and one common stockpurchase.

(c) 1997 American Health Consultants. All rights reserved.